Orpyx® Secures $20 Million in Funding to Revolutionize Diabetes Care with Personalized Remote Health Solutions

Orpyx®, a pioneering digital therapeutics company, has successfully raised an impressive $20,000,000 in its latest funding round, a testament to the increasing demand for innovative healthcare solutions in the diabetes management space. This significant influx of capital will be instrumental in advancing Orpyx’s mission to extend healthspan for individuals living with diabetes through personalized remote care. The company is renowned for its flagship product, the Orpyx® Sensory Insoles, which are revolutionizing diabetes care by significantly reducing the risk of diabetic foot ulcers—a serious complication that can lead to amputation. By integrating advanced data science methodologies with a dedicated remote patient monitoring team of credentialed providers and nurses, Orpyx is transforming the way diabetic patients receive care. This funding will enable the company to enhance its technology, expand its clinical programs, and reach more patients, providing them with the tools they need to take control of their health. The emphasis on a whole-person approach not only addresses immediate health concerns but also seeks to empower individuals to prevent debilitating complications associated with diabetes. With this new financial backing, Orpyx is better positioned to innovate continuously, expand its product offerings, and ultimately make a lasting impact on the diabetes community, ensuring that more individuals can live healthier, longer lives. Stay tuned for the exciting developments that Orpyx will bring to the forefront of diabetes care in the months ahead.